Skip to main content

Table 1 Demographic and clinical characteristics of patients between the different groups

From: Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Variables

All patients (n = 70) *

CRAFITY-low (n = 25) *

CRAFITY-intermediate (n = 29) *

CRAFITY-high (n = 16) *

P value

Age (yrs)

53.84 ± 10.37

52.00 ± 11.88

53.69 ± 10.35

57.00 ± 7.23

0.557

Gender

    

0.305

 Male

58 (82.86%)

23 (92.00%)

22 (75.86%)

13 (81.25%)

 

 Female

12 (17.14%)

2 (8.00%)

7 (24.14%)

3 (18.75%)

 

Pathogeny

    

0.712

 HBV-related

54 (77.14%)

20 (80.00%)

23 (79.31%)

11 (68.75%)

 

 Others

16 (22.86%)

5 (20.00%)

6 (20.69%)

5 (31.25%)

 

ECOG Score

    

0.647

 0

47 (67.14%)

15 (60.00%)

21 (72.41%)

11 (68.75%)

 

 1

23 (32.86%)

10 (40.00%)

8 (27.59%)

5 (31.25%)

 

Child-Pugh class

    

0.184

 A

56 (80.00%)

20 (80.00%)

26 (89.66%)

11 (68.75%)

 

 B

14 (20.00%)

5 (20.00%)

3 (10.34%)

5 (31.25%)

 

ALT (u/L)

38.11 ± 23.83

32.44 ± 19.49

42.69 ± 21.90

38.69 ± 31.85

0.203

AST (u/L)

57.99 ± 62.18

44.28 ± 22.27

70.66 ± 86.57

56.44 ± 48.72

0.379

AFP (ng/mL)

    

< 0.001

 < 100

34 (48.8%)

25 (100.00%)

9 (31.03%)

0 (0.00%)

 

 ≥ 100

36 (51.2%)

0 (0.00%)

20 (68.97%)

16 (100.00%)

 

CRP (mg/dL)

0.59 ± 0.51

0.18 ± 0.12

0.57 ± 0.45

1.26 ± 0.19

< 0.001

PLR

149.36 ± 97.96

113.27 ± 58.64

167.05 ± 110.44

173.66 ± 111.67

0.092

NLR

3.33 ± 2.82

2.61 ± 1.70

3.97 ± 3.76

3.30 ± 2.01

0.260

Types of TKIs

    

0.461

 Sorafanib

17 (24.29%)

7 (28.00%)

4 (13.79%)

6 (37.50%)

 

 Apatinib

26 (37.14%)

8 (32.00%)

13 (44.83%)

5 (31.25%)

 

 Lenvatinib

27 (38.57%)

10 (40.00%)

12 (41.38%)

5 (31.25%)

 

Types of ICIs

    

0.829

 camrelizumab

60 (85.71%)

22 (88.00%)

25 (86.21%)

13 (81.25%)

 

 sintilimab

10 (14.29%)

3 (12.00%)

4 (13.79%)

3 (18.75%)

 

TACE sessions

4.11 ± 2.88

4.80 ± 2.91

3.48 ± 1.66

4.19 ± 4.23

0.221

BCLC stage

    

0.109

 B

28 (40.00%)

14 (56.00%)

10 (34.48%)

4 (25.00%)

 

 C

42 (60.00%)

11 (44.00%)

19 (65.52%)

12 (75.00%)

 

Tumor number

    

0.150

 1

24 (34.28%)

11 (44.00%)

6 (20.69%)

7 (43.75%)

 

 ≥ 2

46 (65.72%)

14 (56.00%)

23 (79.31%)

9 (56.25%)

 

Tumor size (cm)

    

0.098

 ≤ 5

17 (24.29%)

5 (20.00%)

7 (24.14%)

5 (31.25%)

 

 5 ~ 10

33 (47.14%)

15 (60.00%)

15 (51.72%)

3 (18.75%)

 

 ≥ 10

20 (28.57%)

5 (20.00%)

7 (24.14%)

8 (50.00%)

 
  1. HBV, Hepatitis B virus infection; ECOG, Eastern Cooperative Oncology Group; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; CRP, C-reactive protein; PLR, platelet/lymphocyte ratio; NLR, neutrophil/lymphocyte ratio; TKIs, tyrosine kinase inhibitors; TACE, transarterial chemoembolization; BCLC Barcelona Clinic Liver Cancer
  2. * Except where indicated, data are numbers of patients, with percentages in parentheses, or means ± standard deviations
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us